

Molecular Cancer Therapeutics

A Journal of the American Association for Cancer Research

Volume 3, Number 8

August 2004

Articles

p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas 895

Jian-Zhong Qin, Lawrence Stennett, Patricia Bacon, Barbara Bodner,
Mary J.C. Hendrix, Richard E.B. Seftor, Elisabeth A. Seftor, Naira V. Margaryan,
Pamela M. Pollock, Amy Curtis, Jeffrey M. Trent, Frank Bennett, Lucio Miele,
and Brian J. Nickoloff

Characterization of inhibitors of specific carboxylesterases: Development of carboxylesterase inhibitors for translational application 903

Kyoung Jin P. Yoon, Janice L. Hyatt, Christopher L. Morton, Richard E. Lee,
Philip M. Potter, and Mary K. Danks

The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer 911

Terry Y-K. Chow, Moulay A. Alaoui-Jamali, Chiaoli Yeh, Leonard Yuen, and David Griller

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer 921

Daniel E.H. Afar, Vinay Bhaskar, Eric Ibsen, Danna Breinberg, Susan M. Henshall,
James G. Kench, Marija Drobnjak, Rick Powers, Melanie Wong, Ferdinand Evangelista,
Chris O'Hara, David Powers, Robert B. DuBridg, Ingrid Caras, Ruth Winter,
Terri Anderson, Nanette Solvason, Phillip D. Stricker, Carlos Cordon-Cardo,
Howard I. Scher, John J. Grygiel, Robert L. Sutherland, Richard Murray,
Vanitha Ramakrishnan, and Debbie A. Law

Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery 933

Vaqar Mustafa Adhami, Moammir Hasan Aziz, Shannon R. Reagan-Shaw,
Minakshi Nihal, Hasan Mukhtar, and Nihal Ahmad

Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: Single origin, divergent evolution, and multiple outcomes 941

Jeannie E. Maglione, Erik T. McGoldrick, Lawrence J.T. Young, Ruria Namba,
Jeffrey P. Gregg, Lin Liu, Drew Moghanaki, Lesley G. Ellies, Alexander D. Borowsky,
Robert D. Cardiff, and Carol L. MacLeod

Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells 955

Mikael Rinne, David Caldwell, and Mark R. Kelley

Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody 969

Alexander L. Rakhmilevich, Andrea T. Hooper, Daniel J. Hicklin, and Paul M. Sondel

contents continued

Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model 977
David Raben, Cataldo Bianco, Vincenzo Damiano, Roberto Bianco, Davide Melisi, Chiara Mignogna, Francesco Paolo D'Armiento, Luca Cionini, A. Raffaele Bianco, Giampaolo Tortora, Fortunato Ciardiello, and Paul Bunn

Inhibition of constitutively activated nuclear factor- κ B radiosensitizes human melanoma cells . . . 985
Anupama Munshi, John F. Kurland, Takashi Nishikawa, Paul J. Chiao, Michael Andreeff, and Raymond E. Meyn

Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets 993
Cathrine M. Holland, Samir A. Saidi, Amanda L. Evans, Andrew M. Sharkey, John A. Latimer, Robin A.F. Crawford, D. Stephen Charnock-Jones, Cristin G. Print, and Stephen K. Smith

Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation 1003
Liang Liu, Joel B. Berletch, Jessica G. Green, Mitchell S. Pate, Lucy G. Andrews, and Trygve O. Tollefsbol


Retinoid X receptor- γ and peroxisome proliferator-activated receptor- γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment 1011
Joshua P. Klopper, William R. Hays, Vibha Sharma, Margaret A. Baumbusch, Jerome M. Hershman, and Bryan R. Haugen

Minireviews

Altered Hsp90 function in cancer: A unique therapeutic opportunity 1021
Rochelle Bagatell and Luke Whitesell

Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? 1031
Mark A. Hull, Stanley C.W. Ko, and Gillian Hawcroft

Information for Authors i



On the Cover

Rapid internalization of TMEFF2 in prostate cancer cells in culture. The *TMEFF2* gene encodes a plasma membrane protein with limited normal tissue distribution and high overexpression in prostate cancer. The images show binding of a specific monoclonal antibody (mAb) to TMEFF2 protein on the surface of prostate cancer cells at 4°C (*upper panel*), and the rapid and efficient internalization of the mAb-antigen complex at 37°C (*lower panel*). Internalization is essential for an antibody-drug-conjugate (ADC) approach to cancer therapy, where drug release is dependent on lysosomal protease activity. A cathepsin B sensitive anti-TMEFF2 ADC was used to show specific cell killing and antitumor effects in prostate cancer xenograft models, validating it as a potential new therapy for the treatment of prostate cancer. For details, see Afar et al. in this issue.